Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain mahoney from sewage in Japan

Journal of Medical Virology

Volumn 68, Issue 3, 2002, Pages 445-451

  Horie, Hitoshi ^a,d   Yoshida, Hiromu ^b   Matsuura, Kumiko ^c   Miyazawa, Miwako ^a   Wakabayashi, Kengo ^a   Nomoto, Akio ^d   Hashizume, So ^a  

^a Japan Poliomyelitis Research Institute   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c TOYAMA INSTITUTE OF HEALTH   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Inactivated poliovirus vaccine; MAPREC; Oral poliomyelitis vaccine; Polio eradication; Vaccine derived poliovirus

Indexed keywords

INACTIVATED VACCINE; NEUTRALIZING ANTIBODY; ORAL POLIOMYELITIS VACCINE;

ANIMAL CELL; ANTIBODY TITER; ARTICLE; ERADICATION THERAPY; HERD; HUMAN; JAPAN; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS 1; POLYMERASE CHAIN REACTION; SEWAGE; TEMPERATURE SENSITIVITY; VIRUS IMMUNITY; VIRUS ISOLATION; VIRUS MUTANT; VIRUS NEUTRALIZATION; VIRUS STRAIN; VIRUS VIRULENCE; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; HUMANS; JAPAN; MUTATION; NEUTRALIZATION TESTS; PLAQUE ASSAY; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; POLYMERASE CHAIN REACTION; RESTRICTION MAPPING; SEWAGE; TEMPERATURE; VIRULENCE; VIRUS REPLICATION;

POLIOVIRUS;

EID: 0036836636     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10224     Document Type: Article

References (47)

1. Benyesh-Melnick M, Melnisck JL, Rawls WE, Wimberly I, Oro JB, Ben-Porath E, Rennick V. 1967. Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administration during the winter. Am J Epidemiol 86:112-136.
2. Centers for Disease Control and Prevention. 2000. Outbreak of poliomyelitis-Dominican Republic and Haiti, 2000. MMWR 49: 1094-1103.
3. Centers for Disease Control and Prevention. 2001a. Circulation of a type 2 vaccine-derived poliovirus-Egypt, 1982-1993. MMWR 50: 41-42-51.
4. Centers for Disease Control and Prevention. 2001b. Public health dispatch: Acute flaccid paralysis associated with circulating vaccine-derived poliovirus-Philippines, 2001. MMWR 50:874-875.
5. Christodoulou C, Colber-Garapin F, Macadam A, Taffs LF, Marsden S, Minor PD, Horaud F. 1990. Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. J Virol 64:4922-4929.
6. Chumakov KM. 1999. Molecular consistency monitoring of oral poliovirus vaccine and other live viral vaccines. Dev Biol 100:67-74.
7. Chumakov KM, Powers LB, Noonan KE, Roninson IB, Levenbook IS. 1991. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc Natl Acad Sci USA 88:199-203.
8. Chumakov KM, Dragunsky EM, Norwood LP, Douthitt MP, Ran Y, Taffs RE, Ridge J, Levenbook IS. 1994. Consistent selection of mutations in the 5′-untranslated region of oral poliovirus vaccine upon passaging in vitro. J Med Virol 42:79-85.
9. Contreras G, Dimock K, Furesz J, Gardell C, Hazlett D, Karpinski K, McCorkle G, Wu L. 1992. Genetic characterization of Sabin type 1 and 3 poliovaccine virus following serial passage in the human intestinal tract. Biologicals 20:15-26.
10. Dunn G, Begg NT, Cammack N, Minor PD. 1990. Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. J Med Virol 32:92-95.
11. Evans DMA, Dunn G, Minor PD, Schild GC, Cann AJ, Stanway G, Almond JW, Currey K, Maizel JV. 1985. Increased neurovirulence associated with a single nucleotide change in a non-coding region of the Sabin type 3 poliovaccine genome. Nature 314:548-550.
12. Georgescu MM, Balanant J, Macadam A, Otelea D, Combiescu M, Combiscu AA, Crainic R, Delpeyroux F. 1997. Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. J Virol 71:7758-7768.
13. Holland J, Spindler K, Horodyski F, Grabau E, Nichol S, Vande Pol S. 1982. Rapid evolution of RNA genomes. Science 215:1577-1585.
14. Horie H, Koike S, Kurata T, Sato-Yoshida Y, Ise I, Ota Y, Abe S, Hioki K, Kato H, Taya C, Nomura T, Hashizume S, Yonekawa H, Nomoto A. 1994. Transgenic mice carrying the human poliovirus receptor: new animal model for study of poliovirus neurovirulence. J Virol 68:681-688.
15. Horie H, Tano Y, Doi Y, Hashizume S. 1998. Estimation of the neuro-virulence of poliovirus by non-radioisotope molecular analysis to quantify genomic changes. Biologicals 26:289-297.
16. Horie H, Sato-Miyazawa M, Ota Y, Wakabayashi K, Doi T, Yoshizawa K, Doi Y, Hashizume S. 1999. Detection of mutants in polio vaccine viruses using pooled antipoliovirus monoclonal antibodies. Biologicals 27:217-226.
17. Horie H, Miyazawa M, Ota Y, Wakabayashi K, Yoshida H, Doi Y, Hashizume S. 2001. Analysis of the accumulation of mutants in Sabin attenuated polio vaccine viruses passaged in Vero cells. Vaccine 19:1456-1459.
18. Horie H, Yoshida H, Matsuura K, Miyazawa M, Ota Y, Nakayama T, Doi Y, Hashizume S. 2002. Neurovirulence of type 1 polioviruses isolated from sewage in Japan. Appl Environ Microbiol 68:138-142.
19. Kawamura N, Kohara M, Abe S, Komatsu T, Tago K, Arita M, Nomoto A. 1989. Determinants in the 5′ non coding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J Virol 63: 1302-1309.
20. Kohara M, Omata T, Kameda A, Semler BL, Itoh H, Wimmer E, Nomoto A. 1985. In vitro phenotypic markers of a poliovirus recombinant constructed from infectious cDNA clones of the neurovirulent Mahoney strain and the attenuated Sabin 1 strain. J Virol 54:786-792.
21. Koike S, Taya C, Kurata T, Abe S, Ise I, Yonekawa H, Nomoto A. 1991. Transgenic mice susceptible to poliovirus. Proc Natl Acad Sci USA 88:951-955.
22. Macadam AJ, Pollard SR, Ferguson G, Dunn G, Skuce R, Almond JW, Minor PD. 1991. The 5′ noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. Virology 181:451-458.
23. Matsuura K, Ishikura M, Yoshida H, Nakayama T, Hasegawa S, Ando S, Horie H, Miyamura T, Kitamura T. 2000. Assessment of poliovirus eradication in Japan: genomic analysis of the polioviruses isolated from the river water and the sewage in Toyama Prefecture. Appl Environ Microbiol 66:5087-5091.
24. Matyasova I, Koza J. 1982. Properties of poliovirus strains isolated over the period 1969-1978 from the main municipal sewerage system of the City of Prague. J Hyg Epidemiol Microbiol Immunol 26:162-175.
25. Melnick JL. 1978. Advantages and disadvantages of killed and live poliomyelitis vaccines. Bull World Health Organ 56:21-38.
26. Melnick JL. 1984. Live attenuated oral poliovirus vaccine. Rev Infect Dis 6(suppl):323-327.
27. Mulders MN, Reimerink JH, Stenvik M, Alaeddionoglu I, van der Avoort HG, Hovi T, Koopmans MP. 1999. A Sabin vaccine-derived field isolate of poliovirus type 1 displaying aberrant phenotypic and genetic features, including a deletion in antigenic site 1. J Gen Virol 80(pt 4):907-916.
28. Muzychenko AR, Lipskaya GY, Maslova AV, Svitkin YV, Pilipenko EV, Nottay BK, Kew OM, Agol VI. 1991. Coupled mutation in the 5′-untranslated region of the Sabin poliovirus strains during in vivo passages: structural and functional implications. Virus Res 21: 111-122.
29. Nakano JH, Hatch MH, Thieme ML, Nottay B. 1978. Parameters for differentiating vaccine-derived and wild poliovirus strains. Prog Med Virol 24:178-206.
30. Nkowane BM, Wassilak SGF, Orenstein WA, Bart KJ, Schonberger LB, Hinman AR, Kew OM. 1987. Vaccine-associated paralytic poliomyelitis, United States: 1973 through 1984. JAMA 257:1335-1340.
31. Nomoto A, Koike S. 1992. Molecular mechanisms of poliovirus pathogenesis. In: Roos RP, editor. Molecular neurovirology. Totowa, NJ: Humana Press. p 251-281.
32. Pollard SR, Dunn G, Cammack N, Minor PD, Almond JW. 1989. Nucleotide sequence of a neurovirulent variant of the Type 2 oral poliovirus vaccine. J Virol 63:4949-4951.
33. Poyry T, Stenvik M, Hovi T. 1988. Viruses in sewage waters during and after a poliomyelitis outbreak and subsequent nationwide oral poliovirus vaccination campaign in Finland. Appl Environ Microbiol 54:371-374.
34. Prevots DR, Sutter RW, Strebel PM, Weibel RE, Cochi SL. 1994. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991: implications for estimating the risk of vaccine-associated disease. Arch Pediatr Adolesc Med 148:479-485.
35. Rezapkin GV, Chumakov KM, Lu Z, Ran Y, Dragunsky EM, Levenbook IS. 1994. Microevolution of Sabin 1 strain in vitro and genetic stability of oral poliovirus vaccine. Virology 202:370-378.
36. Sabin AB. 1981. Paralytic poliomyelitis: old dogmas and new perspectives. Rev Infect Dis 3:543-564.
37. Sabin AB, Boulger LR. 1973. History of Sabin attenuated poliovirus oral live vaccine strains. J Biol Stand 1:115-118.
38. Salk JE. 1960. Persistence of immunity after administration of formalin-treated poliovirus vaccine. Lancet 2:715-723.
39. Tambini G, Andrus JK, Marques E, Boshell J, Pallansch M, de Quadros CA, Kew OM. 1993. Direct detection of wild poliovirus circulation by stool surveys of healthy children and analysis of community wastewater. J Infect Dis 168:1510-1514.
40. Ward CD, Stockes MAM, Flanegan JB. 1988. Direct measurement of the poliovirus RNA polymerase error frequency in vitro. J Virol 62: 558-562.
41. Westrop GD, Wareham KA, Davis DM, Dunn G, Minor PD, Magrath DI, Taffs F, Marsden S, Skinner MA, Schild GC, Almond JW. 1989. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol 63:1338-1344.
42. Wood DJ, Macadam AJ. 1997. Laboratory tests for live attenuated poliovirus vaccines. Biologicals 25:3-15.
43. World Health Organization. 1990a. Requirements for poliomyelitis vaccine. WHO Expert Committee on Biological Standardization. Tech Rep Ser 800:30-65.
44. World Health Organization. 1990b. Manual for the virological investigation of poliomyelitis. World Health Organization, Expanded Programme on Immunization and Division of Communicable Diseases. WHO publication no. WHO/EPI/CDS/ POLIO/90.1 Geneva, Switzerland: World Health Organization.
45. World Health Organization. 1995. Manual of laboratory methods for potency testing of vaccines used in the WHO Expanded Programme on Immunization. WHO publication no. WHO/BLG/95.1. Geneva, Switzerland: World Health Organization.
46. Yoshida H, Horie H, Matsuura K, Miyamura T. 2000. Characterization of polioviruses isolated from sewage and river water in Japan. Lancet 356:1461-1463.
47. Yoshida H, Horie H, Matsuura K, Kitamura T, Hashizume S, Miyamura T. 2002. Prevalence of vaccine-derived polioviruses in the environment. J Gen Virol 83:1107-1111.